Immunization News and Research RSS Feed - Immunization News and Research

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
Not all pediatricians recommend HPV vaccine for eleven- and twelve-year olds

Not all pediatricians recommend HPV vaccine for eleven- and twelve-year olds

In a society that has become increasingly suspicious of vaccines, it's not only parents who stand in the way of some children getting vaccinated for human papillomavirus (HPV). A new study published in Pediatrics shows not all pediatricians are recommending or even discussing the HPV virus for eleven- and twelve-year olds. [More]
Pacemaker Induced Transient Asynchrony could help slow down progression of heart failure

Pacemaker Induced Transient Asynchrony could help slow down progression of heart failure

Johns Hopkins has demonstrated in animals that applying a pacemaker's mild electrical shocks to push the heart in and out of normal synchronized contraction for part of each day may be an effective way to slow down the progression of heart failure, a disorder that afflicts millions of Americans. [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy. [More]
New study pinpoints five top risk factors responsible for undernutrition among children in India

New study pinpoints five top risk factors responsible for undernutrition among children in India

In India, nearly 40% of all children are stunted--of extremely low height for their age--and nearly 30% are underweight. A new study from Harvard T.H. Chan School of Public Health has now pinpointed the five top risk factors responsible for more than two-thirds of the problem. [More]
More effort needed to reduce risks of mosquito-transmitted epidemics in the U.S. and Mexico

More effort needed to reduce risks of mosquito-transmitted epidemics in the U.S. and Mexico

Despite the increasing risks of mosquito-transmitted epidemics in the United States and Mexico, policymakers in both countries have made little effort to prevent future outbreaks, according to a new policy brief by tropical-disease and science policy experts at Rice University's Baker Institute for Public Policy. [More]
Incorporating postpartum contraceptive services across the continuum of reproductive healthcare

Incorporating postpartum contraceptive services across the continuum of reproductive healthcare

Approximately one-quarter of inter-birth intervals in low- and middle-income countries are less than 24 months in length, exposing infants to risks of prematurity, low birthweight, and death. Increased evidence of these health risks has emerged in the past few decades and, after a period of neglect, interest in postpartum family planning has followed, supported by organizations like WHO and USAID. [More]
New framework launched for global elimination of human rabies

New framework launched for global elimination of human rabies

A new framework to eliminate human rabies and save tens of thousands of lives each year has been launched today by the World Health Organization, the World Organization for Animal Health, the Food and Agriculture Organization of the United Nations and the Global Alliance for the Control of Rabies. [More]
Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac gets approval to begin clinical trials on Sabin Inactivated Polio Vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or "sIPV") candidate. [More]
Home intervention, education improve vaccination rates in at-risk children

Home intervention, education improve vaccination rates in at-risk children

A program by Stony Brook Children's Hospital that involves the use of trained community health workers on child immunization reveals that home intervention and education improves vaccine/immunization rates in at-risk children, including those living in poverty. [More]
Green Cross' GCFlu Quadrivalent approved to protect against four influenza strains in South Korea

Green Cross' GCFlu Quadrivalent approved to protect against four influenza strains in South Korea

Green Cross Corporation, a South Korean biopharmaceutical company, announced today that South Korea's Ministry of Food and Drug Safety has approved GCFLU QUADRIVALENT (Influenza Virus Vaccine) for immunisation of adults to help prevent disease caused by seasonal influenza (flu) virus subtype A and B. GCFlu Quadrivalent is the first locally-manufactured vaccine to cover against four influenza strains. [More]
Seqirus announces FDA approval of Fluad for seasonal influenza

Seqirus announces FDA approval of Fluad for seasonal influenza

Seqirus announced today that the US Food and Drug Administration has approved Fluad (Influenza Vaccine, Adjuvanted) to help protect those aged 65 years and older against seasonal influenza. Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older. [More]
Women & Infants Hospital recognized as 2014 Top Performer on Key Quality Measures

Women & Infants Hospital recognized as 2014 Top Performer on Key Quality Measures

Women & Infants Hospital of Rhode Island, a Care New England hospital, announced today that it has been recognized as a 2014 Top Performer on Key Quality Measures by The Joint Commission, the leading accreditor of health care organizations in the U.S. [More]
Analyzing potential TB vaccine

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats. [More]
Measles vaccination plays key role in reducing child mortality

Measles vaccination plays key role in reducing child mortality

The number of measles-related deaths has decreased 79% from 546 800 at the beginning of the century to 114 900 in 2014. New data released by WHO for the Measles & Rubella Initiative, estimates that 17.1 million lives have been saved since 2000, largely due to increased vaccination coverage against this highly contagious viral disease. [More]
GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue. [More]
New vaccine candidate shows great promise at fighting respiratory syncytial virus

New vaccine candidate shows great promise at fighting respiratory syncytial virus

Johns Hopkins Bloomberg School of Public Health researchers say a new candidate vaccine against respiratory syncytial virus (RSV) made with a weakened version of the virus shows great promise at fighting the disease, the leading cause of hospitalization for children under the age of one in the U.S. [More]
Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHME

Deaths from avoidable risk factors: an interview with Dr Ali Mokdad, IHME

The study showed that about thirty percent to maybe half of the leading causes of death in the world are preventable. These are risk factors that you could manage and thus you could prevent a lot of premature deaths. [More]
Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013. [More]
Advertisement
Advertisement